Welcome to our dedicated page for Tempest Therapeutics news (Ticker: TPST), a resource for investors and traders seeking the latest updates and insights on Tempest Therapeutics stock.
Tempest Therapeutics Inc (TPST) is a clinical-stage biotechnology company pioneering small molecule therapies targeting cancer through immuno-oncology innovation. This page serves as the definitive source for verified news and official announcements related to TPST's research, clinical trials, and corporate developments.
Investors and researchers will find timely updates on key milestones including clinical trial results, regulatory filings, and strategic partnerships. The curated content spans financial disclosures, scientific advancements in tumor immunity modulation, and operational updates from leadership.
Our news collection prioritizes accuracy and relevance, offering:
- Real-time updates on TPST's therapeutic pipeline progress
- Analysis of quarterly earnings and SEC filings
- Coverage of peer-reviewed research publications
- Updates on intellectual property developments
Bookmark this page for streamlined access to TPST's evolving story in cancer treatment innovation. Check regularly for authoritative reporting on developments impacting both patient care and investment considerations.
Tempest Therapeutics (Nasdaq: TPST) announced the acceptance of an abstract for the 2023 ASCO Annual Meeting, scheduled for June 2-6, 2023, in Chicago. The abstract focuses on TPST-1495, an EP2/EP4 prostaglandin receptor dual antagonist.
Presentation Details:
- Title: A Phase 1 study of TPST-1495 as a single agent and in combination with pembrolizumab in patients with advanced solid tumors
- Session Title: Developmental Therapeutics — Molecularly Targeted Agents and Tumor Biology
- Session Date and Time: June 3, 2023; 8:00 a.m. – 11:00 a.m. ET
- Abstract Number: 3107
The abstract will be released on May 25, 2023, at 5:00 p.m. ET on the ASCO website.
Tempest Therapeutics, Inc. (Nasdaq: TPST) recently presented new data from its TPST-1120 and TREX1 programs at the 2023 American Association for Cancer Research Annual Meeting. The findings from TPST-1120, an oral PPAR⍺ antagonist, highlighted biomarker changes linked to drug exposure and response levels in patients undergoing treatment in a Phase 1 trial. Additionally, the TREX1 inhibitor program showcased novel human TREX1 enzyme structures, paving the way for potent inhibitors targeting the STING pathway. The company aims to advance TPST-1120 through multiple oncology indications and initiate human trials for the TREX1 inhibitors. Initial results from ongoing trials are expected soon, indicating promising possibilities for future cancer therapies.
Tempest Therapeutics, Inc. (TPST) reported significant clinical progress in 2022, highlighted by the completion of a Phase 1 study for TPST-1120, indicating a 30% objective response rate in patients unresponsive to traditional therapies. The randomization study in collaboration with Roche for first-line hepatocellular carcinoma (HCC) patients is fully enrolled, with data expected in mid-2023. Financially, Tempest saw a decline in cash reserves to $31.2 million and a net loss of $35.7 million for the year. However, the company anticipates adequate funding through Q2 2024, with ongoing developments in TPST-1495 and a promising TREX1 inhibitor program.
FAQ
What is the current stock price of Tempest Therapeutics (TPST)?
What is the market cap of Tempest Therapeutics (TPST)?
